Compare Motorola Solutions Inc (MSI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Sana Biotechnology Inc — how do they compare? Motorola Solutions Inc trades at $444.19 (market cap $74.00B), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: Motorola Solutions Inc is far larger — about 88.4× Sana Biotechnology Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and Sana Biotechnology Inc for 23 Days on average.
| MSI | SANA | |
|---|---|---|
Market Cap | $74.00B | $836.71M |
Volume | 722,147 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $491.24 | $5.92 |
52-Week Low | $363.83 | $2.68 |
Typical Hold Time | 100 Days | 23 Days |
Enterprise Value | $82.90B | $749.96M |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $443.80, down 1.04% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and net income of $2.15B, supported by a record $15.6B backlog as of Q2 2026 (Zacks Investment Research, 2026-09-28). Recent acquisitions like D-Fend Solutions for $1.5B expand its security portfolio, while a new $2B share repurchase authorization signals confidence (Business Wire, 2026-09-09).
The outlook is positive with a consensus price target of $525.86, implying 18.5% upside, and 71% of analysts rate it a Buy. Risks include elevated debt levels with a debt-to-asset ratio of 47.29% in 2025 and negative net cash flow trends, but strong public safety contract wins and AI integration in video analytics provide growth catalysts.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
